Thylacine Bio is developing a peptide platform that targets conserved regions of respiratory viruses to create potent antivirals that treat illness, prevent infection, and block transmission. This technology enables rapid adaptation to emerging pathogens, providing scalable solutions for pandemic preparedness and protection against multiple viral threats.
Funding
$476K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current antiviral treatments often struggle to keep pace with the rapid mutation rates of respiratory viruses, leading to reduced efficacy and the emergence of resistant strains. Traditional antiviral development is slow and often cannot respond quickly to emerging pandemic threats or provide broad protection against multiple viral strains.
Solution
Thylacine Bio is developing a peptide-based antiviral platform that targets highly conserved regions across multiple respiratory viruses, providing broad-spectrum protection and reducing the likelihood of resistance. The platform enables rapid design and production of antiviral therapeutics that can treat existing infections, prevent new infections, and block viral transmission. These antivirals are designed for easy self-administration and distribution, offering a scalable solution for both endemic respiratory viruses and emerging pandemic threats. By focusing on conserved viral regions, Thylacine Bio aims to create resilient therapeutics that maintain efficacy across viral variants.
Target Audience
The primary target audience includes public health organizations preparing for pandemics, as well as individuals at high risk of contracting respiratory viruses.
Features
- Peptide-based platform targeting conserved regions of respiratory viruses
- Broad-spectrum antiviral activity against multiple viral strains
- Rapidly adaptable to new and emerging pathogens
- Designed to treat illness, prevent infection, and block transmission
- Potential for self-administration and easy distribution